Jian Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1487808/publications.pdf

Version: 2024-02-01

201674 276875 4,564 65 27 41 citations h-index g-index papers 66 66 66 9381 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGF \hat{I}^2 Signaling. Cancer Research, 2020, 80, 1819-1832.	0.9	17
2	Alterations in TGF- \hat{l}^2 signaling leads to high HMGA2 levels potentially through modulation of PJA1/SMAD3 in HCC cells. Genes and Cancer, 2020, 11, 43-52.	1.9	8
3	Dysregulated PJA1-TGF-β signaling in cancer stem cell-associated liver cancers. Oncoscience, 2020, 7, 88-95.	2.2	9
4	Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget, 2020, 11, 1186-1201.	1.8	27
5	Immunomodulatory TGF- \hat{l}^2 Signaling in Hepatocellular Carcinoma. Trends in Molecular Medicine, 2019, 25, 1010-1023.	6.7	157
6	Su1024 – The Role of E3 Ligase Pja1 in Proliferation and Tumorigenesis of Hepatocellular Carcinoma. Gastroenterology, 2019, 156, S-1267.	1.3	0
7	Abstract 3382: A pan-cancer analysis reveals high frequency genetic alterations in mediators of signaling by the TGF- \hat{l}^2 superfamily. , 2019, , .		2
8	ZC3H12A Expression in Different Stages of Colorectal Cancer. Oncoscience, 2019, 6, 301-311.	2.2	10
9	Abstract 3382: A pan-cancer analysis reveals high frequency genetic alterations in mediators of signaling by the TGF- \hat{l}^2 superfamily. , 2019, , .		O
10	Abstract 4443: Targeting E3 ligase PJA1 via TGF- \hat{l}^2 pathway in hepatocellular carcinoma. , 2019, , .		0
11	Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. Trends in Molecular Medicine, 2018, 24, 395-411.	6.7	58
12	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell, 2018, 33, 401-416.e8.	16.8	215
13	Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-Î ² Pathway. Gastroenterology, 2018, 154, 195-210.	1.3	105
14	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î ² Superfamily. Cell Systems, 2018, 7, 422-437.e7.	6.2	134
15	Mo 1971 - Crosstalk Between Ceacam and Tgf- \hat{l}^2 Signaling Pathways and their Role in Colorectal Cancer. Gastroenterology, 2018, 154, S-868.	1.3	O
16	522 - Stem Cell Homeostasis in Liver Cancers is Regulated by TGF- \hat{l}^2 -IGF2 Axis. Gastroenterology, 2018, 154, S-116.	1.3	0
17	1047 - Targeting E3 Ligase PJA1 Through TGF-Î ² Pathway in Hepatocellular Carcinoma. Gastroenterology, 2018, 154, S-1114.	1.3	O
18	Sa1464 - Role of BETA2 Spectrin and SMAD3 in Alcohol-Induced Liver Injury and Liver Stem Cell Homeostasis. Gastroenterology, 2018, 154, S-1122.	1.3	0

#	Article	IF	CITATIONS
19	Abstract 5459: Regulation of IGF2 by TGF- \hat{I}^2 signaling in liver cancers and stem cell homeostasis. , 2018, , .		O
20	Abstract 2226: TGF- \hat{l}^2 and CEACAMs regulated biomarkers detect early colorectal cancer. , 2018, , .		0
21	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169, 1327-1341.e23.	28.9	1,794
22	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers. Science Translational Medicine, 2017, 9, .	12.4	174
23	Cellular Interactions of TGF- \hat{l}^2 Pathway Members and Epigenetic Regulators of Liver and Gastrointestinal Cancers. Gastroenterology, 2017, 152, S1159.	1.3	0
24	Loss of the transforming growth factorâ€Î² effector β2â€Spectrin promotes genomic instability. Hepatology, 2017, 65, 678-693.	7.3	31
25	IL6â€mediated inflammatory loop reprograms normal to epithelialâ€mesenchymal transition+ metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta–deficient β2â€spectrin+/â°' mice. Hepatology, 2017, 65, 1222-1236.	7.3	56
26	PRAJA is overexpressed in glioblastoma and contributes to neural precursor development. Genes and Cancer, 2017, 8, 640-649.	1.9	11
27	Abstract 5330: Targeting hepatocellular carcinoma through TGF- \hat{l}^2 pathway E3 ligases. , 2017, , .		0
28	Mutations of Chromatin Structure Regulating Genes in Human Malignancies. Current Protein and Peptide Science, 2016, 17, 411-437.	1.4	25
29	Mutational Profiles Reveal an Aberrant TGF-Î ² -CEA Regulated Pathway in Colon Adenomas. PLoS ONE, 2016, 11, e0153933.	2,5	17
30	Vitamin D Deficiency Promotes Liver Tumor Growth in Transforming Growth Factor- $\hat{1}^2$ /Smad3-Deficient Mice Through Wnt and Toll-like Receptor 7 Pathway Modulation. Scientific Reports, 2016, 6, 30217.	3.3	43
31	Tu 1624 Dysregulated TGF- \hat{l}^2 Signaling Leads to Genomic Instability and Liver Cancer. Gastroenterology, 2016, 150, S1152.	1.3	0
32	TGF- \hat{l}^2/\hat{l}^2 2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. Journal of Clinical Investigation, 2016, 126, 527-542.	8.2	39
33	Abstract 3594: The TGF- \hat{l}^2 effector \hat{l}^2 2SP depletion abrogates DNA damage repair. , 2016, , .		0
34	Abstract 4425: Comprehensive study of TGF- \hat{l}^2 pathway-driven functional molecular characterization of human hepatocellular cancer. , 2016, , .		0
35	Pathogenesis of Hepatocellular Carcinoma Development in Non-alcoholic Fatty Liver Disease. Current Hepatology Reports, 2015, 14, 119-127.	0.9	15
36	The cell cycle regulator $14-3-3\ddot{l}f$ opposes and reverses cancer metabolic reprogramming. Nature Communications, 2015, 6, 7530.	12.8	65

#	Article	lF	CITATIONS
37	Sa 1914 The Genomic Landscape of Human Colon Adenomas Reveals Early Driver Mutations and a TGF- \hat{l}^2 -CEA Regulated Profile. Gastroenterology, 2015, 148, S-353-S-354.	1.3	O
38	Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer, 2015, 15, 215.	2.6	95
39	The Landscape of DNA Virus Associations Across Human Cancers. , 2015, , 303-315.		1
40	CSN6 positively regulates c-Jun in a MEKK1-dependent manner. Cell Cycle, 2015, 14, 3079-3087.	2.6	10
41	Abstract 892: Vitamin D deficiency regulates TLR7 to promote hepatocellular cancer in TGF- \hat{l}^2 /Smad3 heterozygous mice., 2015,,.		0
42	Abstract 67: Genomic and mutational profiling of human colon adenomas reveals early driver mutations and a TGF- \hat{l}^2 -CEA regulated profile. , 2015, , .		0
43	LEIGClong non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. BMC Cancer, 2014, 14, 932.	2.6	70
44	Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Research, 2014, 16, 475.	5.0	302
45	Effects of Obesity on Transcriptomic Changes and Cancer Hallmarks in Estrogen Receptor–Positive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	87
46	Sa1928 Whole Genome Analysis of Colon Adenomas Reveals Novel Prognostic and Therapeutic Targets. Gastroenterology, 2014, 146, S-331.	1.3	0
47	CSN6 drives carcinogenesis by positively regulating Myc stability. Nature Communications, 2014, 5, 5384.	12.8	67
48	Generation of a mouse model of T-cell lymphoma based on chronic LPS challenge and TGF- \hat{l}^2 signaling disruption. Genes and Cancer, 2014, 5, 348-352.	1.9	6
49	Abstract 4703: Genome & exome analysis of early colon cancers reveals new targets. , 2014, , .		0
50	Targeting TGF-Î ² signaling in cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 743-760.	3.4	183
51	DNA Damage-Mediated c-Myc Degradation Requires 14-3-3 Sigma. Cancer Hallmarks, 2013, 1, 3-17.	0.8	14
52	Ubiquitination-Mediated p57Kip2 Degradation by CSN5 Confers Cancer Cell Proliferation. Cancer Hallmarks, 2013, 1, 133-144.	0.8	6
53	Abstract 5198: Targeting E3 ligase PRAJA1 in hepatocellular cancer , 2013, , .		0
54	Abstract 1763: Frequency of homologous recombination repair defects across breast cancer subtypes., 2013, , .		0

#	Article	IF	CITATIONS
55	HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell Cycle, 2012, 11, 4181-4190.	2.6	37
56	Aurora B kinase phosphorylates and instigates degradation of p53. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1513-22.	7.1	155
57	Exenatide improves glucocorticoid-induced glucose intolerance in mice. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2011, 4, 61.	2.4	11
58	The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. Journal of Cellular and Molecular Medicine, 2011, 15, 825-836.	3.6	70
59	14-3-3Ïf Exerts Tumor-Suppressor Activity Mediated by Regulation of COP1 Stability. Cancer Research, 2011, 71, 884-894.	0.9	55
60	Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. Journal of Clinical Investigation, 2011, 121, 851-865.	8.2	99
61	Nuclear export regulation of COP1 by 14-3-3 $\ddot{l}f$ in response to DNA damage. Molecular Cancer, 2010, 9, 243.	19.2	40
62	Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Molecular Cancer, 2010, 9, 42.	19.2	80
63	Abstract 457: Hypoxia-mediated upregulation of Pim-1 contributes to tumor survival. , 2010, , .		1
64	Hypoxia-Mediated Up-Regulation of Pim-1 Contributes to Solid Tumor Formation. American Journal of Pathology, 2009, 175, 400-411.	3.8	89
65	Roles for CSN5 in control of p53/MDM2 activities. Journal of Cellular Biochemistry, 2008, 103, 1219-1230.	2.6	74